Harnessing the precision of sound for easier drug delivery.
From infusion to injection for patient-friendly therapies.
.png)
WHAT WE DO
Drug delivery, simplified.
We help drug developers formulate new and existing biologic products into ultra-high-concentration subcutaneous injections. Leveraging our proprietary acoustophoretic technology, drugs traditionally administered through lengthy hospital-based intravenous injections can now be delivered via small-volume injection.
.png)
Our platform brings
life-saving drug delivery
from the hospital to your home.
Why subcutaneous delivery?
.png)
Why aren't more products like this?
The challenge is formulation. To enable small-volume subcutaneous dosing, monoclonal antibodies must be formulated at very high concentrations. At these levels, mAbs often become highly viscous and unstable, making them difficult to manufacture, process, and inject. As a result, fewer than half of approved mAbs are available in subcutaneous form, typically limited to lower-dose products or those requiring large injection volumes.
Many patients must travel to hospitals or infusion centers for IV therapies that can take hours to administer and strain both patients and healthcare resources. Subcutaneous delivery offers a simpler alternative. By enabling faster, more convenient dosing outside of infusion settings, subcutaneous formulations can improve patient comfort and adherence while reducing burden on clinics and care teams. It’s no surprise that most patients prefer subcutaneous injections over IV infusions; this approach benefits patients, drug developers, and the healthcare system alike.
We create ultra-high concentrations of biologics, exceeding 500 mg/mL.
Our microgel suspension formulations are designed to achieve the optimal concentrations and characteristics necessary for effective subcutaneous delivery.
OUR TECHNOLOGY
Our process is characterized by its gentle handling and versatility, accommodating a broad spectrum of materials with minimal product loss.
-Daniele Foresti, Founder
OUR SOLUTION DELIVERS
Low viscosity
Particle suspensions allow us to overcome the viscosity
limitation.
Less aggregation
mAbs are stabilized within a polymer matrix resulting in less antibody aggregation.
Greater stability
Higher payload concentrations are encapsulated.
Easier injections
Painless subcutaneous injections allow for self-administration.
Safer access
Better drug delivery means less severe immune responses.
Reduced cost
Increased savings for patients, providers, and pharmaceutical companies alike.
IN THE NEWS
ARPA-H Investor Catalyst Hub | October 2024
.png)
Follow us for updates
